1 Department of Respiratory and Critical Care Medicine, The People's Hospital of Neijiang Dongxing District, Neijiang, China 2 Department of Respiratory and Critical Care Medicine, The First ...

People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly extend their survivorship with fewer toxic side effects, a new study shows.

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

The Beverage Testing Institute (BevTest) doesn’t hand out medals easily. For decades, BTI’s panels have blind-tasted thousands of whiskies, tracking not just the occasional superstar but the labels ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Stage 2 lymphoma is localized, affecting lymph nodes or a single extranodal site on one diaphragm side, with a favorable prognosis. Diagnosis involves biopsies, blood tests, and imaging to confirm ...

Named after the 19th-century scientist who first described abnormal masses in the lymph nodes, Hodgkin lymphoma is a cancer of the lymphatic system. Around 10% of lymphoma diagnoses are categorized as ...

Lymphoma originates in lymphocytes and is classified into Hodgkin and Non-Hodgkin types, each with unique features and treatment approaches. Early-stage lymphoma is localized, often with a high cure ...

The Leukemia & Lymphoma Society is marking September’s Blood Cancer Awareness Month by rebranding and rolling out its first national advertising campaign in more than a decade. Now named Blood Cancer ...

It’s easy to dismiss random, flu-like symptoms as a sign that you’re coming down with something. But when they stick around for weeks and seem to be getting worse, it’s fair to have questions. While ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...